Benefits of Contemporary Implantable Cardioverter Defibrillators in Patients With Improved Ejection Fraction: When is the Most Clinically Relevant Time to Evaluate?-Reply

Selcuk Adabag^{1

2}, Kristen K Patton³, Alfred E Buxton⁴

Affiliations

¹ Division of Cardiology, Department of Medicine, Veterans Affairs Health Care System, Minneapolis, Minnesota.
² Division of Cardiovascular Diseases, University of Minnesota, Minneapolis.
³ Division of Cardiology, Department of Medicine, University of Washington, Seattle.
⁴ Department of Medicine, Cardiovascular Division, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.

Comment

Selcuk Adabag et al. JAMA Cardiol. 2017.

. 2017 Dec 1;2(12):1397-1398.

doi: 10.1001/jamacardio.2017.3458.

Selcuk Adabag^{1

2}, Kristen K Patton³, Alfred E Buxton⁴

¹ Division of Cardiology, Department of Medicine, Veterans Affairs Health Care System, Minneapolis, Minnesota.
² Division of Cardiovascular Diseases, University of Minnesota, Minneapolis.
³ Division of Cardiology, Department of Medicine, University of Washington, Seattle.
⁴ Department of Medicine, Cardiovascular Division, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.

No abstract available

Comment on

Association of Implantable Cardioverter Defibrillators With Survival in Patients With and Without Improved Ejection Fraction: Secondary Analysis of the Sudden Cardiac Death in Heart Failure Trial.
Adabag S, Patton KK, Buxton AE, Rector TS, Ensrud KE, Vakil K, Levy WC, Poole JE. Adabag S, et al. JAMA Cardiol. 2017 Jul 1;2(7):767-774. doi: 10.1001/jamacardio.2017.1413. JAMA Cardiol. 2017. PMID: 28724134 Free PMC article.
Benefits of Contemporary Implantable Cardioverter Defibrillators in Patients With Improved Ejection Fraction: When Is the Most Clinically Relevant Time to Evaluate?
Nishimura M, Thomas I, Hsu JC. Nishimura M, et al. JAMA Cardiol. 2017 Dec 1;2(12):1397. doi: 10.1001/jamacardio.2017.3448. JAMA Cardiol. 2017. PMID: 28973138 No abstract available.